Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy

Minehiko Inomata 1,*, Kenji Azechi 1, Naoki Takata 1, Kana Hayashi 1, Kotaro Tokui 1, Chihiro Taka 1, Seisuke Okazawa 1, Kenta Kambara 1, Shingo Imanishi 1, Toshiro Miwa 1, Ryuji Hayashi 2, Shoko Matsui 1 and Kazuyuki Tobe 1

1 First Department of Internal Medicine, Toyama University Hospital, Toyama 930-0194, Japan; cont2dct@gmail.com (K.A.); leftsideback2@gmail.com (N.T.); canape@med.u-toyama.ac.jp (K.H.); tokui@med.u-toyama.ac.jp (K.T.); mameciroro@gmail.com (C.T.); okazawa@med.u-toyama.ac.jp (S.O.); kkent@med.u-toyama.ac.jp (K.K.); shingo@med.u-toyama.ac.jp (S.I.); mtoshi-tym@umin.ac.jp (T.M.); smatsui@med.u-toyama.ac.jp (S.M.); tobe@med.u-toyama.ac.jp (K.T.)

2 Department of Medical Oncology, Toyama University Hospital, Toyama 930-0194, Japan; hsayaka@med.u-toyama.ac.jp

* Correspondence: 9446-tym@umin.org; Tel.: +81-76-434-7287

Received: 8 November 2020; Accepted: 24 November 2020; Published: 25 November 2020

Abstract: Background: Among patients with non-small cell lung cancer (NSCLC), we compared the progression-free survival (PFS) and proportion of acquisition of T790M mutation of the epidermal growth receptor gene (EGFR) after first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patient groups with and without tumor expression of programmed death ligand-1 (PD-L1). Methods: Data of patients with EGFR-mutant NSCLC were retrospectively analyzed. Tumor PD-L1 expression was evaluated by immunohistochemistry using the 22C3 antibody. T790M gene mutation was analyzed in 27 patients. Results: Data of 47 patients with EGFR-mutant NSCLC were analyzed. The median (95% confidence interval) PFS in the PD-L1-negative and -positive patient groups were 12.9 (9.7–15.4) months and 9.0 (5.1–12.3) months, respectively ($p = 0.029$). T790M gene mutation was analyzed in 27 patients. The proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI was higher in the PD-L1-negative patient group than in the PD-L1-positive patient group (8/11 patients (72.7%) vs. 4/16 patients (25.0%); $p = 0.022$). Conclusions: Patients with negative tumor PD-L1 expression showed longer PFS and a higher proportion of acquisition of T790M mutation of EGFR after first-line treatment with an EGFR-TKI.

Keywords: epidermal growth factor receptor; lung cancer; T790M; prognosis; programmed death ligand-1

1. Introduction

In patients with EGFR-mutant non-small cell lung cancer (NSCLC), treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to yield significantly longer progression-free survival (PFS) periods as compared to treatment with cytotoxic agents [1,2]. However, most patients receiving EGFR-TKI treatment develop acquired resistance to the drug sooner or later. The most common mechanism of resistance is acquisition of the T790M mutation of EGFR; a phase III trial has demonstrated that treatment with osimertinib, a third-generation EGFR-TKI,
was associated with significantly longer PFS, as compared to cytotoxic agents, in patients with acquired resistance to first-line EGFR-TKI treatment who had acquired T790M [3]. Previous studies have reported an association of the PFS with the presence/absence of T790M, and also associations of the duration of first-line EGFR-TKI treatment [4–7], and presence of exon 19 deletion of EGFR [5,7] with the likelihood of detection of T790M.

Tumor expression of programmed death ligand-1 (PD-L1) has been shown to be associated with the efficacy of immune checkpoint inhibitors in patients with non-squamous NSCLC [8], whereas immune checkpoint inhibitors are known to be less effective in patients with EGFR-mutant NSCLC [9,10]. On the other hand, there are several reports on the relationship between tumor PD-L1 expression and the PFS after EGFR-TKI treatment [11–15]. Although inconsistent results have been reported, tumor PD-L1 expression could affect the clinical course in patients with EGFR-mutant NSCLC. Furthermore, EGFR-mutant NSCLC patients who developed resistance to EGFR-TKIs via acquisition of T790M showed lower tumor PD-L1 expression levels and also a lower proportion of patients with positive tumor PD-L1 expression [16,17].

Based on these previous reports, we analyzed the data of EGFR-mutant NSCLC patients to compare the PFS and proportion of acquisition of T790M after first-line treatment with EGFR-TKIs in patient groups with and without PD-L1 expression.

2. Materials and Methods

2.1. Study Design and Patient Selection

We reviewed the medical charts of patients with NSCLC treated at Toyama University Hospital and conducted a retrospective analysis of the data. The inclusion criteria were as follows: (1) patients with cytologically or histologically confirmed NSCLC harboring sensitive EGFR mutations; and (2) patients treated with EGFR-TKIs including gefitinib, erlotinib, or osimertinib as first-line treatment between 2014 and 2019. The exclusion criterion was patients whose records lacked data on the tumor PD-L1 status.

The PFS of patients with EGFR-mutant NSCLC treated with EGFR-TKIs was determined. The disease stage was evaluated according to the 8th edition of the UICC TNM classification, and patients who had undergone surgery were re-classified based on the findings at the start of the EGFR-TKI treatment. Then, analysis of the proportion of acquisition of T790M was conducted in patients in whom the T790M status was evaluated after failure of first-line treatment with a 1st- or 2nd-generation EGFR-TKI.

This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labour and Welfare of Japan), after obtaining the approval of the Ethics committee, University of Toyama (Reference number: R2019180, 10 March 2020). The informed consent of the study was waived by the ethics committee of university of Toyama, and we disclosed information about the study instead of obtaining written informed consent.

2.2. Immunohistochemistry

PD-L1 expression was evaluated in formalin-fixed and paraffin-embedded tumor tissue specimens by immunohistochemistry using the 22C3 antibody (BML, Tokyo, Japan). The proportion of PD-L1-positive tumor cells was calculated as the tumor proportion score (TPS), and a TPS of 1% or more was defined as positive.

2.3. Polymerase Chain Reaction

The presence of T790M was evaluated by the Cobas EGFR real-time PCR assay (LSI Medience, Tokyo, Japan) using tissues or humoral specimens obtained after the patients developed resistance to the EGFR-TKI used (15 patients: tissue specimens, nine patients: blood samples, two patients:
cerebrospinal fluid, and one patient: pleural effusion). The minimum detection sensitivity for T790M mutation is reported to be 0.1% when using a plasma sample (https://www.info.pmda.go.jp/downfiles/ivd/PDF/700025_22800EZX00011000_A_01_10.pdf).

2.4. Statistical Analysis

Patients were dichotomized according to categorical variables or the median levels. Survival curves were drawn by the Kaplan-Meier method.

PFS was calculated from the date of initiation of treatment with an EGFR-TKI until the date of diagnosis of disease progression or occurrence of death due to any cause, and censored at the last visit at which no disease progression was observed. The relationships between the PFS and clinical parameters were analyzed by the log-rank test. Multivariate analysis was performed using a Cox proportional hazard model. EGFR status, performance status, lactate dehydrogenase level, disease stage, and PD-L1 expression were planned to be used as independent variables. The associations of the clinical parameters with the proportion of acquisition of T790M after first-line treatment with an EGFR-TKI were analyzed by Fisher’s exact test. Statistical analysis was performed using JMP ver. 14.0.2 (SAS, Cary, NC, USA).

3. Results

3.1. Patient Selection

Between 2014 and 2019, 67 patients with EGFR-mutant NSCLC received first-line treatment with EGFR-TKIs. Of these, 20 cases whose records lacked the data on tumor PD-L1 expression were excluded, and the data of the remaining 47 patients were analyzed to determine the PFS. Then, after a total of 20 patients, including 12 patients who were treated with osimertinib, 18 patients whose records lacked data on the T790M gene mutation status, and 13 patients who did not show disease progression were excluded, and the data of the remaining 27 patients were analyzed to determine the presence/absence of T790M (Figure 1).

![Figure 1. Patient selection. Of the data of 67 patients with EGFR-mutant NSCLC who had received first-line treatment with EGFR-TKIs, those of 47 patients were analyzed to determine the PFS and those of 27 patients were analyzed to determine the proportion of acquisition of the T790M mutation of EGFR.](image-url)
3.2. PFS

Table 1 shows the patient characteristics. Forty-four of the 47 patients (93.6%) had lung adenocarcinoma, two (4.3%) had NSCLC (not otherwise specified), and one (2.1%) had adenosquamous cell lung cancer. Exon 19 deletion was detected in 16 (34.0%) patients, exon 21 L858R in 28 (59.6%) patients, exon 18 G719A in two (4.3%) patients, and exon 21 L861Q in one (2.1%) patient. The TPS of PD-L1 was ≥1% in 29 of the 47 (61.7%) patients. Tumor PD-L1 expression was evaluated using tumor specimen obtained after the first-line treatment with an EGFR-TKI in five patients, because the tissue specimens obtained before the first-line treatment were not available.

|                  | 47 (100%) |
|------------------|-----------|
| **Age (yr)**     |           |
| <70              | 23 (48.9%)|
| ≥70              | 24 (51.1%)|
| **Sex**          |           |
| Male             | 20 (42.6%)|
| Female           | 27 (57.4%)|
| **Smoking history** |       |
| Yes              | 17 (36.2%)|
| No               | 30 (63.8%)|
| **PS**           |           |
| 0–1              | 38 (80.9%)|
| ≥2               | 9 (19.1%) |
| **Histology**    |           |
| Adenocarcinoma   | 44 (93.6%)|
| Others           | 3 (6.4%)  |
| **EGFR mutation** |         |
| Exon 19 Deletion | 16 (34.0%)|
| Exon 21 L858R    | 28 (59.6%)|
| Others           | 3 (6.4%)  |
| **LDH**          |           |
| <200 IU/L        | 21 (44.7%)|
| ≥200 IU/L        | 26 (55.3%)|
| **Brain metastasis** |     |
| Yes              | 18 (38.3%)|
| No               | 29 (61.7%)|
| **TNM classification (T)** | |
| T1-2             | 22 (46.8%)|
| T3-4             | 25 (53.2%)|
| **TNM classification (N)** | |
| N0-1             | 22 (46.8%)|
| N2-3             | 25 (53.2%)|
| **TNM classification (M)** |       |
| M0-1a            | 14 (29.8%)|
| M1b-1c           | 33 (70.2%)|
| **Disease stage**     |       |
| IIIA-C/IVA       | 20 (42.6%)|
| IVB               | 27 (57.4%)|
| **EGFR-TKI**     |           |
| Gefitinib        | 13 (27.7%)|
| Erlotinib        | 8 (17.0%) |
| Afatinib         | 15 (31.9%)|
| Osimertinib      | 11 (23.4%)|
| **PD-L1**        |           |
| Positive         | 29 (61.7%)|
| Negative         | 18 (38.3%)|

EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase; PS, performance status; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.

Figure 2 shows the association between the tumor PD-L1 expression status and the PFS. The median (95% confidence interval) PFS periods in the PD-L1-negative and PD-L1-positive patients were 12.9 (9.7–15.4) months and 9.0 (5.1–12.3) months, respectively (\(p = 0.029\), log-rank test). Analysis limited to patients in whom tumor PD-L1 expression was evaluated in tissue specimens obtained before the start of the first-line EGFR-TKI treatment showed similar results (median PFS, 12.9 vs. 7.4 months, \(p = 0.027\), log-rank test). No significant associations of other baseline characteristics with the PFS were observed (Table 2). Multivariate analysis revealed a significant association between PD-L1 expression and PFS (Table 3).
PFS were observed (Table 2). Multivariate analysis revealed a significant association between PD-L1 expression and PFS (Table 3). PD-L1 status (positive vs. negative) was not associated with clinical parameters, including age (<70 vs. ≥70, \(p = 1.000\)), sex (male vs. female, \(p = 1.000\)), smoking history (yes vs. no, \(p = 0.211\)), histology (adenocarcinoma vs. others, \(p = 0.276\)), EGFR mutation (Exon 19 del vs. Exon 21 L858R vs. others, \(p = 0.789\)), PS (0–1 vs. ≥2, \(p = 0.716\)), LDH (<200 IU/L vs. ≥200 IU/L, \(p = 0.130\)), brain metastasis (yes vs. no, \(p = 0.759\)), and stage (IIIA-C/IVA vs. IVB, \(p = 1.000\)) (Fisher’s exact test).

In the present study, three patients with uncommon mutation were enrolled in the analysis, including two patients with exon 18 G719A and one patient with exon 21 L861Q. The log-rank test revealed that median PFS after the initiation of treatment with EGFR-TKI was as short as 7.7 months compared to patients with common sensitive EGFR mutation (\(p = 0.308\), log-rank test). However, the Cox regression hazard model suggested that there is an association between tumor PD-L1 expression and PFS after the initiation of treatment with EGFR-TKI independently of EGFR mutation status.

**Figure 2.** Kaplan-Meier curve for PFS after the initiation of first-line EGFR-TKI treatment in patients with and without tumor PD-L1 expression. Solid line: Patients with negative tumor PD-L1 expression; dashed line: Patients with positive tumor PD-L1 expression. The PD-L1-negative patient group showed a longer PFS than the PD-L1-positive patient group (\(p = 0.029\), log-rank test).

**Table 2.** Associations of the patient characteristics with the PFS (log-rank test).

| Characteristic                  | PFS        | \(p\)  |
|-------------------------------|------------|--------|
| Age (yr)                      |            |        |
| <70                           | 9.7 (5.9–13.8) | 0.564  |
| ≥70                           | 12.8 (7.4–13.2)  |        |
| Sex                           |            |        |
| Male                          | 9.7 (5.9–15.4)  | 0.713  |
| Female                        | 11.2 (5.6–12.9)  |        |
| Smoking history               |            |        |
| Yes                           | 12.3 (7.4–15.9)  | 0.681  |
| No                            | 10.7 (5.9–12.9)  |        |
| PS                            |            |        |
| 0–1                           | 11.2 (7.7–12.9)  | 0.561  |
| ≥2                            | 10.7 (1.5–13.8)  |        |
| Histology                     |            |        |
| Adenocarcinoma                | 11.2 (7.9–12.9)  | 0.436  |
| Others                        | 9.1 (2.0–13.8)  |        |
| EGFR mutation                 |            |        |
| Exon 19 Deletion              | 11.5 (9.1–15.9)  | 0.308  |
| Exon 21 L858R                 | 10.7 (5.9–13.2)  |        |
| Others                        | 7.7 (2.5–13.8)  |        |
| LDH                           |            |        |
| <200 IU/L                     | 11.5 (7.9–13.8)  | 0.320  |
| ≥200 IU/L                     | 9.1 (5.1–12.9)  |        |
| Brain metastasis              |            |        |
| Yes                           | 8.8 (5.9–12.9)  | 0.329  |
| No                            | 12.3 (9.0–14.1)  |        |
| TNM classification (T)        |            |        |
| T1-2                          | 12.8 (7.7–15.4)  | 0.621  |
| T3-4                          | 10.5 (5.6–12.9)  |        |
| TNM classification (N)        |            |        |
| N0-1                          | 11.5 (8.6–15.9)  | 0.132  |
| N2-3                          | 10.7 (5.1–12.9)  |        |
| TNM classification (M)        |            |        |
| M0-1a                         | 12.3 (2.5–14.1)  | 0.304  |
| M1b-1c                        | 9.7 (7.4–12.9)  |        |
| Disease stage                 |            |        |
| IIIA-C/IVA                    | 12.8 (9.0–14.1)  | 0.245  |
| IVB                           | 9.1 (5.9–12.9)  |        |
| EGFR-TKI                      |            |        |
| Gefitinib                     | 12.8 (4.5–15.9)  | 0.608  |
| Erlotinib                     | 8.8 (2.5–14.1)  |        |
| Afatinib                      | 11.5 (4.6–13.8)  |        |
| Osimertinib                   | Not reached  |        |
| PD-L1                         |            |        |
| Positive                      | 9.0 (5.1–12.3)  | 0.029  |
| Negative                      | 12.9 (9.7–15.4)  |        |

EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase; PS, performance status; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.
Table 3. Associations of the patient characteristics with the PFS (Cox proportional hazards model).

|                          | HR (95% CI)   | p   |
|--------------------------|---------------|-----|
| EGFR mutation            |               |     |
| Exon 19 deletion         | 0.49 (0.21–1.16) | 0.106 |
| Exon 21 L858R            | 1             |     |
| Others                   | 1.27 (0.30–5.41) | 0.749 |
| PS                       |               |     |
| 0–1                      | 1.15 (0.44–3.03) | 0.775 |
| ≥2                       | 1             |     |
| LDH                      |               |     |
| <200 IU/L                | 0.85 (0.37–1.97) | 0.710 |
| ≥200 IU/L                | 1             |     |
| Disease stage            |               |     |
| IIIA-C/IVA               | 0.50 (0.21–1.16) | 0.105 |
| IVB                      | 1             |     |
| PD-L1                    |               |     |
| Positive                 | 2.84 (1.20–6.72) | 0.018 |
| Negative                 | 1             |     |

EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase; PS, performance status; PD-L1, programmed death ligand-1.

PD-L1 status (positive vs. negative) was not associated with clinical parameters, including age (<70 vs. ≥70, p = 1.000), sex (male vs. female, p = 1.000), smoking history (yes vs. no, p = 0.211), histology (adenocarcinoma vs. others, p = 0.276), EGFR mutation (Exon 19 del vs. Exon 21 L858R vs. others, p = 0.789), PS (0–1 vs. ≥2, p = 0.716), LDH (<200 IU/L vs. ≥200 IU/L, p = 0.130), brain metastasis (yes vs. no, p = 0.759), and stage (IIIA-C/IVA vs. IVB, p = 1.000) (Fisher’s exact test).

In the present study, three patients with uncommon mutation were enrolled in the analysis, including two patients with exon 18 G719A and one patient with exon 21 L861Q. The log-rank test revealed that median PFS after the initiation of treatment with EGFR-TKI was as short as 7.7 months compared to patients with common sensitive EGFR mutation (p = 0.308, log-rank test). However, the Cox regression hazard model suggested that there is an association between tumor PD-L1 expression and PFS after the initiation of treatment with EGFR-TKI independently of EGFR mutation status.

3.3. Acquisition of T790M

Table 4 shows the relationships between the patient characteristics and the proportion of acquisition of T790M after patients had developed resistance to the first-line EGFR-TKI treatment. The presence/absence of T790M was evaluated using tissue specimens in 15 cases (55.6%) and humoral specimens in 12 cases (44.4%); T790M was detected in 12 patients (44.4%). The PD-L1-negative group showed a higher proportion of acquisition of T790M than the PD-L1-positive group (8/11 patients (72.7%) vs. 4/16 patients (25.0%); p = 0.022, Fisher’s exact test). Analysis limited to patients in whom the tumor PD-L1 expression was evaluated in tissue specimens obtained before the start of the first-line EGFR-TKI treatment showed similar results (7/10 patients (70.0%) vs. 3/12 patients (25.0%); p = 0.084, Fisher’s exact test). There were no significant associations between the patient characteristics, except for the tumor PD-L1 expression status, and the proportion of acquisition of T790M.
### Table 4. Associations of the patient characteristics with the status of acquisition of the T790M mutation of EGFR.

| Characteristic                | Whole | T790M-Positive | T790M-Negative | p     |
|-------------------------------|-------|----------------|----------------|-------|
| **Whole**                     | 27    | 12 (44.4%)     | 15 (55.6%)     |       |
| **Age (yr)**                  |       |                |                |       |
| <70                           | 18    | 7 (38.9%)      | 11 (61.1%)     | 0.448 |
| ≥70                           | 9     | 5 (55.6%)      | 4 (44.4%)      |       |
| **Sex**                       |       |                |                |       |
| Male                          | 16    | 6 (37.5%)      | 10 (62.5%)     | 0.452 |
| Female                        | 11    | 6 (54.6%)      | 5 (45.5%)      |       |
| **Smoking history**           |       |                |                |       |
| Yes                           | 13    | 6 (46.2%)      | 7 (53.9%)      | 1.000 |
| No                            | 14    | 6 (42.9%)      | 8 (57.1%)      |       |
| **Histology**                 |       |                |                |       |
| Adenocarcinoma                | 24    | 11 (45.8%)     | 13 (54.2%)     | 1.000 |
| Others                        | 3     | 1 (33.3%)      | 2 (66.7%)      |       |
| **PS**                        |       |                |                |       |
| 0–1                           | 18    | 7 (38.9%)      | 11 (61.1%)     | 0.412 |
| ≥2                            | 9     | 5 (55.6%)      | 4 (44.4%)      |       |
| **EGFR mutation**             |       |                |                |       |
| Exon 19 Deletion              | 9     | 6 (66.7%)      | 3 (33.3%)      | 0.217 |
| Exon 21 L858R                 | 17    | 6 (35.3%)      | 11 (64.7%)     |       |
| Others                        | 1     | 0 (0%)         | 1 (100%)       |       |
| **LDH**                       |       |                |                |       |
| <200 IU/L                     | 14    | 8 (57.1%)      | 6 (42.9%)      | 0.252 |
| ≥200 IU/L                     | 13    | 4 (30.8%)      | 9 (69.2%)      |       |
| **Brain metastasis**          |       |                |                |       |
| Yes                           | 13    | 6 (46.2%)      | 7 (53.9%)      | 1.000 |
| No                            | 14    | 6 (42.9%)      | 8 (57.1%)      |       |
| **EGFR-TKI**                  |       |                |                |       |
| Gefitinib                     | 9     | 6 (66.7%)      | 3 (33.3%)      | 0.243 |
| Erlotinib                     | 7     | 3 (42.9%)      | 4 (57.1%)      |       |
| Afatinib                      | 11    | 3 (27.3%)      | 8 (72.3%)      |       |
| **PD-L1**                     |       |                |                |       |
| Positive                      | 16    | 4 (25.0%)      | 12 (75.0%)     | 0.022 |
| Negative                      | 11    | 8 (72.7%)      | 3 (27.3%)      |       |

EGFR, epidermal growth factor receptor; LDH, lactate dehydrogenase; PS, performance status; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.

Figure 3 shows the associations of the EGFR gene mutation and tumor PD-L1 expression status with the proportion of acquisition of T790M. The PD-L1-negative patient group, both among patients with exon 19 del and exon 21 L858 mutations of EGFR, showed a higher proportion of acquisition of T790M (Exon 19 del: PD-L1 negative: 4/4 (100%) vs. PD-L1 positive: 2/5 (40.0%); exon 21 L858R; PD-L1-negative: 4/7 (57.1%) vs. PD-L1-positive: 2/10 (20.0%), p = 0.045, Fisher’s exact test).

![Figure 3](image-url)
4. Discussion

The results of the present study showed that negative tumor PD-L1 expression in patients with
EGFR-mutant NSCLC as evaluated using the 22C3 antibody was associated with a longer PFS and a
higher proportion of acquisition of T790M after first-line treatment with an EGFR-TKI in patients with
EGFR-mutant NSCLC.

Several studies have evaluated the relationship between tumor PD-L1 expression and the efficacy
of EGFR-TKI therapy in patients with EGFR-mutant NSCLC, but no consistent results have been
reported. The present study, conducted using the 22C3 antibody for immunohistochemical evaluation
of tumor PD-L1 expression, showed that positive tumor PD-L1 expression was associated with shorter
PFS, consistent with the results reported by Soo et al., who used the SP142 antibody for evaluating
tumor PD-L1 expression [14]. Lin et al. and D’Incecco et al. reported contrasting results; they found
that the PFS was longer in patients with positive tumor PD-L1 expression. They used a common
yet different antibody for the PD-L1 immunohistochemistry [12,13]. It is possible that the results of
PD-L1 immunohistochemistry obtained using different antibodies reflect different biological aspects of
the tumor.

It is reported that patients with acquired T790M after failure of treatment with an EGFR-TKI
show lower tumor PD-L1 expression levels or a lower proportion of patients with positive tumor
PD-L1 expression [16,17]. The findings of the present study seem to be in line with these previous
reports and suggest that the tumor PD-L1 status could be used to predict the likelihood of acquisition
of T790M. However, in five of our 27 patients in whom we evaluated the tumor PD-L1 expression,
the evaluation was conducted in tumor tissue specimens obtained after the initiation of first-line
EGFR-TKI treatment. Nevertheless, we obtained similar results when the analysis was limited to
patients in whom the tumor PD-L1 status was evaluated in tumor tissue specimens obtained before the
initiation of EGFR-TKI treatment.

Several studies have reported that the proportion of acquisition of T790M is higher in patients
with exon 19 deletion mutation of EGFR [5,7]. The findings of our study (Figure 3) suggest that the
tumor PD-L1 status is associated with the likelihood of acquisition of T790M, independent of the EGFR
mutation, that is, exon 19 deletion or exon 21 L858R. However, because the sample size in the present
study was small, it is necessary to verify the findings in a larger clinical study.

There were several limitations of the present study. First, the study was a retrospective study
conducted in a small number of patients. Therefore, the statistical power was limited, and random
errors and selection bias could have influenced the results of the analysis. Second, in five of the
27 patients, the tumor PD-L1 expression was evaluated using tissue samples obtained after the initiation
of EGFR-TKI treatment, and there are reports to suggest that the tumor PD-L1 status could change
during treatment [17,18]. Because of these limitations, verification of our results in a larger patient
series is necessary.

In conclusion, in patients with EGFR-mutant NSCLC enrolled in this study, the presence/absence
of tumor PD-L1 expression was associated with the PFS and the proportion of acquisition of the T790M
mutation of EGFR after first-line treatment with EGFR-TKIs. Although the results must be verified
further, evaluation of tumor PD-L1 expression as a biomarker in patients with EGFR-mutant NSCLC is
expected in the future.

Author Contributions: Conceptualization, M.I.; methodology, M.I.; investigation, M.I., K.A., N.T., K.H., K.T., C.T.,
S.O., K.K., S.I., T.M., and R.H.; writing—original draft preparation, M.I.; writing—review and editing, K.A., N.T.,
K.H., K.T., C.T., S.O., K.K., S.I., T.M., R.H., and S.M.; supervision, K.T. All authors have read and agreed to the
published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N. Engl. J. Med.* 2010, 362, 2380–2388. [CrossRef] [PubMed]

2. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T.; et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. *Lancet Oncol.* 2010, 11, 121–128. [CrossRef]

3. Mok, T.S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N. Engl. J. Med.* 2017, 376, 629–640. [CrossRef] [PubMed]

4. Oya, Y.; Yoshida, T.; Kuroda, H.; Shimizu, J.; Horio, Y.; Sakao, Y.; Inaba, Y.; Hida, T.; Yatabe, Y. Association between EGFR T790M status and progression patterns during initial EGFR-TKI treatment in patients harboring EGFR mutation. *Clin. Lung Cancer* 2017, 18, 698–705.e2. [CrossRef] [PubMed]

5. Joo, J.W.; Hong, M.H.; Shim, H.S. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. *Lung Cancer* 2018, 121, 12–17. [CrossRef] [PubMed]

6. Kawamura, T.; Kenmotsu, H.; Omori, S.; Nakashima, K.; Wakuda, K.; Ono, A.; Naito, T.; Murakami, H.; Omae, K.; Mori, K.; et al. Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer. *Clin. Lung Cancer* 2018, 19, e247–e252. [CrossRef] [PubMed]

7. Huang, Y.H.; Hsu, K.H.; Tseng, J.S.; Chen, K.C.; Huynh, T.G.; Hsu, C.H.; Su, K.Y.; Chen, J.J.W.; Chen, H.W.; Yu, S.L.; Yang, T.Y.; et al. The Association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. *Cancer Res. Treat.* 2018, 50, 1294–1303. [CrossRef] [PubMed]

8. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer. *N. Engl. J. Med.* 2015, 373, 1627–1639. [CrossRef] [PubMed]

9. Gainor, J.F.; Shaw, A.T.; Sequist, L.V.; Fu, X.; Azzoli, C.G.; Piotrowska, Z.; Schultz, K.R.; et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. *Clin. Cancer Res.* 2016, 22, 4585–4593. [CrossRef] [PubMed]

10. Lisberg, A.; Cummings, A.; Goldman, J.W.; Bornazyan, K.; Reese, N.; Wang, T.; Coluzzi, P.; Ledezma, B.; Mendenhall, M.; Hunt, J.; et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+ non-squamous non-small-cell lung cancer. *Clin. Oncol. Oncol.* 2018, 13, 1138–1145. [CrossRef] [PubMed]

11. Tang, Y.; Fang, W.; Zhang, Y.; Hong, S.; Yang, S.; Chen, N.; Zhan, J.; He, X.; Qin, T.; et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-squamous NSCLC patients treated with EGFR-TKIs. *Oncotarget* 2015, 6, 14209–14219. [CrossRef] [PubMed]

12. Lin, C.; Chen, X.; Li, M.; Liu, J.; Qi, X.; Yang, W.; Zhang, H.; Cai, Z.; Dai, Y.; Ouyang, X. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. *Clin. Lung Cancer* 2015, 16, 625–635. [CrossRef] [PubMed]

13. D’Incecco, A.; Andreozzi, M.; Ludovini, V.; Rossi, E.; Capodanno, A.; Landi, L.; Tibaldi, C.; Minuti, G.; Salvini, J.; Coppi, E.; et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. *Br. J. Cancer* 2015, 112, 95–102. [CrossRef] [PubMed]

14. Soo, R.A.; Kim, H.R.; Asuncion, B.R.; Fazreem, Z.; Omar, M.F.M.; Herrera, M.C.; Yun Lim, J.S.; Sia, G.; Soong, R.; Cho, B.C. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. *Lung Cancer* 2017, 105, 17–22. [CrossRef] [PubMed]

15. Su, S.; Dong, Z.Y.; Xie, Z.; Yan, L.X.; Li, Y.F.; Su, J.; Liu, S.Y.; Yin, K.; Chen, R.L.; Huang, S.M.; et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. *J. Thorac. Oncol.* 2018, 13, 1668–1675. [CrossRef] [PubMed]
16. Haratani, K.; Hayashi, H.; Tanaka, T.; Kaneda, H.; Togashi, Y.; Sakai, K.; Hayashi, K.; Tomida, S.; Chiba, Y.; Yonesaka, K.; et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. *Ann. Oncol.* 2017, 28, 1532–1539. [CrossRef] [PubMed]

17. Hata, A.; Katakami, N.; Nanjo, S.; Okuda, C.; Kaji, R.; Masago, K.; Fujita, S.; Yoshida, H.; Zama, K.; Imai, Y.; et al. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. *Lung Cancer* 2017, 111, 182–189. [CrossRef] [PubMed]

18. Kim, T.J.; Hong, S.A.; Kim, O.; Kim, S.J.; Yang, J.H.; Joung, E.K.; Kang, J.H.; Hong, S.H. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. *Oncotarget* 2017, 8, 107630–107639. [CrossRef] [PubMed]

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).